DrugPatentWatch Database Preview

Details for Patent: 6,699,871

« Back to Dashboard

Which drugs does patent 6,699,871 protect, and when does it expire?

Patent 6,699,871 protects JANUMET XR, JANUMET, JANUVIA, JUVISYNC, and STEGLUJAN, and is included in five NDAs.

This patent has sixty-four patent family members in forty-two countries.

Summary for Patent: 6,699,871

Title:	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Abstract:	The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s):	Edmondson; Scott D. (New York, NJ), Fisher; Michael H. (Ringoes, NJ), Kim; Dooseop (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Parmee; Emma R. (Scotch Plains, NJ), Weber; Ann E. (Scotch Plains, NJ), Xu; Jinyou (Scotch Plains, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	10/189,603
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,699,871

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Merck Sharp Dohme	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012		RX	Yes	No			Y	Y		METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp Dohme	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012		RX	Yes	Yes			Y	Y		METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp Dohme	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012		RX	Yes	No			Y	Y		METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp Dohme	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007		RX	Yes	Yes			Y	Y		METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

Non-Orange Book US Patents Family Members for Patent 6,699,871

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,440,668	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes
7,125,873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
8,168,637	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes

International Family Members for US Patent 6,699,871

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036114
Austria	321048
Austria	471148
Australia	2002320303